Abstract Search

ea0056p861 | Pituitary - Clinical | ECE2018

An open-label, multicentre, single-arm, expanded-access study of subcutaneous (s.c.) pasireotide in patients with Cushing’s disease (CD)

Fleseriu Maria , Iweha Chioma , Salgado Luiz , Mazzuco Tania Longo , Patino Heather , Campigotto Federico , Maamari Ricardo , Limumpornpetch Padiporn

Introduction: Pasireotide sc has a proven favourable efficacy and safety profile in CD patients, as shown in clinical trials. Here, we report safety and efficacy results from an expanded-access study designed to allow CD patients to receive pasireotide until regulatory approval for commercial use and reimbursement was obtained in their country.Methods: Pasireotide-naïve adults with CD (mean 24-hour urinary free cortisol [mUFC; of three samples] exce...

0 shares

ea0037ep811 | Pituitary: clinical | ECE2015

Ongoing, open-label, multicenter, expanded-access study demonstrating the safety and efficacy of pasireotide sc in patients with Cushing's disease

Salgado Luiz R , Stalla Gunter K , Mazzuco Tania Longo , Geer Eliza B , Pedroncelli Alberto M , Ye Moncy , Kandra Albert , Limumpornpetch Padiporn

Background: Pasireotide (Signifor®), a multireceptor-targeted somatostatin analogue, was initially approved in Europe and the USA in 2012 for treating adult patients with Cushings disease for whom surgery is not an option/has failed. This expanded-access study allowed patients to receive pasireotide until regulatory approval was obtained in their country, and collected further safety/efficacy data. Here we report an interim analysis of this on...

0 shares

ePoster

Endocrine Abstracts

An open-label, multicentre, single-arm, expanded-access study of subcutaneous (s.c.) pasireotide in patients with Cushing’s disease (CD)

Ongoing, open-label, multicenter, expanded-access study demonstrating the safety and efficacy of pasireotide sc in patients with Cushing's disease

BiosciAbstracts